Bradley R Salonen1, Manpreet S Mundi2, Ryan T Hurt3,2,4,5, Sara L Bonnes3. 1. Division of General Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. salonen.bradley@mayo.edu. 2. Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, MN, USA. 3. Division of General Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. 4. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. 5. Division of Gastroenterology, Hepatology and Nutrition, University of Louisville, Louisville, KY, USA.
Abstract
PURPOSE OF REVIEW: In this review, we examine the role for parenteral nutrition (PN) for nutritional support of patients with advanced, incurable cancer with an emphasis on bridging the divide between expectations and reality. RECENT FINDINGS: As the rates of cancer have continued to rise worldwide, the utility of PN has continued to be studied. Due to multiple reasons, high-quality research studies have been scarce, and much of the data is based on observational studies. The recent trend appears to support the use of PN in carefully selected patients. Importantly, the effect on quality of life also should be considered when deciding to initiate PN. PN can be a supportive lifeline for patients with advanced, incurable cancer. The medical team should consider each patient individually to decide if PN should be offered. It is of paramount important for the medical team to engage in shared decision-making with the patient and caregiver(s) to ensure that PN is aligned with their goals and wishes.
PURPOSE OF REVIEW: In this review, we examine the role for parenteral nutrition (PN) for nutritional support of patients with advanced, incurable cancer with an emphasis on bridging the divide between expectations and reality. RECENT FINDINGS: As the rates of cancer have continued to rise worldwide, the utility of PN has continued to be studied. Due to multiple reasons, high-quality research studies have been scarce, and much of the data is based on observational studies. The recent trend appears to support the use of PN in carefully selected patients. Importantly, the effect on quality of life also should be considered when deciding to initiate PN. PN can be a supportive lifeline for patients with advanced, incurable cancer. The medical team should consider each patient individually to decide if PN should be offered. It is of paramount important for the medical team to engage in shared decision-making with the patient and caregiver(s) to ensure that PN is aligned with their goals and wishes.
Entities:
Keywords:
Cancer; Home parenteral nutrition; Parenteral nutrition
Authors: Jann Arends; Patrick Bachmann; Vickie Baracos; Nicole Barthelemy; Hartmut Bertz; Federico Bozzetti; Ken Fearon; Elisabeth Hütterer; Elizabeth Isenring; Stein Kaasa; Zeljko Krznaric; Barry Laird; Maria Larsson; Alessandro Laviano; Stefan Mühlebach; Maurizio Muscaritoli; Line Oldervoll; Paula Ravasco; Tora Solheim; Florian Strasser; Marian de van der Schueren; Jean-Charles Preiser Journal: Clin Nutr Date: 2016-08-06 Impact factor: 7.324
Authors: Marion F Winkler; Rose Ann DiMaria-Ghalili; Peggi Guenter; Helaine E Resnick; Lawrence Robinson; Beth Lyman; Carol Ireton-Jones; Lillian Harvey Banchik; Ezra Steiger Journal: JPEN J Parenter Enteral Nutr Date: 2015-05-13 Impact factor: 4.016
Authors: Christopher Filtenborg Brandt; Mark Hvistendahl; Rahim M Naimi; Siri Tribler; Michael Staun; Per Brøbech; Palle Bekker Jeppesen Journal: JPEN J Parenter Enteral Nutr Date: 2016-06-20 Impact factor: 4.016
Authors: Lisa Martin; Pierre Senesse; Ioannis Gioulbasanis; Sami Antoun; Federico Bozzetti; Chris Deans; Florian Strasser; Lene Thoresen; R Thomas Jagoe; Martin Chasen; Kent Lundholm; Ingvar Bosaeus; Kenneth H Fearon; Vickie E Baracos Journal: J Clin Oncol Date: 2014-11-24 Impact factor: 44.544
Authors: Paolo Cotogni; Luca De Carli; Roberto Passera; Maria Luisa Amerio; Elena Agnello; Maurizio Fadda; Marta Ossola; Taira Monge; Antonella De Francesco; Federico Bozzetti Journal: Cancer Med Date: 2017-05-29 Impact factor: 4.452
Authors: Trude R Balstad; Erik T Løhre; Lene Thoresen; Morten Thronæs; Laila S Skjelvan; Ragnhild G Helgås; Tora S Solheim; Kari Sand Journal: Oncol Ther Date: 2022-02-24